2024.03.26

Genomtec secures PLN 10.6 million to fund scientific research and development of the oncology project – Company will raise capital from founding shareholders and investors

Genomtec will raise PLN 10.6 million (equivalent to over USD 2.6 million), most of which will be used to fund the research & development of ...
2024.03.12

Genomtec strengthens the Supervisory Board with individuals who bring extensive industry and business experience

Genomtec S.A.,  announces that the Extraordinary General Meeting of Shareholders of the company has appointed two new members to the Supervisory ...
2023.11.13

Genomtec received positive evaluation of Grant in Oncology Diagnostics from the Polish Agency for Enterprise Development (PARP) and the European Funds for a Modern Economy program

The Genomtec project, titled “Development of technology and an automatic system for mutation detection in clinical oncology based on ...
2023.09.28

Genomtec S.A. expands its Genomtec ID platform to oncology and has filed a patent application specific to oncology diagnostics

Genomtec has successfully completed the expansion of its Genomtec ID platform in the field of oncological diagnostics and has filed a patent ...
2023.07.07

The M&A process runs in parallel with research and development activities

– We are concentrating our efforts on multiple areas that are directly linked to the Genomtec ID platform. Our main focus lies in ...
2023.05.30

Genomtec at BIO International Convention

We are pleased to announce that Genomtec team (Miron Tokarski & Charudutt Shah) will attend BIO 2023 from Jun 5-8, 2023 in Boston. ...